By L. Gancka. Pensacola Christian College.
Like other products containing estrogen buy levitra 10mg line, it should be used for the shortest duration consistent with treatment goals and risks for the individual woman discount 10mg levitra overnight delivery. When using this drug only for the prevention of osteoporosis cheap 10mg levitra amex, such use should be limited to women who are at significant risk of osteoporosis and only after carefully considering alternatives that do not contain estrogen. Side effects of conjugated estrogens/bazedoxifene include muscle spasms, nausea, diarrhea, dyspepsia, upper abdominal pain, oropharyngeal pain, dizziness and neck pain. Because this product contains estrogen, it is approved with the same Boxed Warning and other Warnings and Precautions that have been approved with estrogen products. It is also approved for treatment in men and women at high risk of fracture with osteoporosis associated with sustained systemic glucocorticoid 95 therapy. Teriparatide reduces the risk of vertebral fractures by about 65 percent and non-vertebral fragility fractures by about 53 percent in patients with osteoporosis, after an average of 18 months of therapy. Drug administration: Teriparatide is an anabolic (bone-building) agent administered by 20 µg daily subcutaneous injection. Drug safety: Side effects of teriparatide include leg cramps, nausea and dizziness. Because it caused an increase in the incidence of osteosarcoma in rats (high doses, long duration treatment in the rodent), patients with an increased risk of osteosarcoma (e. Denosumab reduces the incidence of vertebral fractures by about 68 percent, hip fractures by about 40 percent and non-vertebral fractures by about 20 percent over three years. Denosumab is also indicated to increase bone mass in men at high risk of fracture, treat bone loss in women with breast cancer on aromatase inhibitor therapies and to treat bone loss in men receiving gonadatropin-reducing hormone treatment for prostate cancer who are at high risk for fracture. Drug administration: Administered by a health professional, 60 mg every six months as a subcutaneous injection. Denosumab increased the risk of serious skin infections (cellulitis) and skin rash. Sequential and Combination Therapy Sequential treatment with anabolic therapy followed by an antiresorptive agent is generally preferred. Combination therapy with teriparatide and an antiresorptive can be considered in a few clinical settings in patients with very severe osteoporosis such as spine and hip fractures. Duration of Treatment No pharmacologic therapy should be considered indefinite in duration. All non-bisphosphonate medications produce temporary effects that wane upon discontinuation. In contrast, bisphosphonates may allow residual effects even after treatment discontinuation. Therefore, it may be possible to discontinue bisphosphonates and retain residual benefits against fracture at least for several years. Since there is no extensive evidence base to guide 97 treatment duration decisions, duration decisions need to be individualized. After the initial three to five year treatment period, a comprehensive risk assessment should be performed. It is reasonable to discontinue bisphosphonates after three to five years in people who appear to be at modest risk of fracture after the initial treatment period. In contrast, for those who appear to be at high risk for fracture, continued treatment with a bisphosphonate or an alternative therapy 98 should be considered. It is also approved for use in hypoparathyroidism, both surgical and idiopathic, and pseudohypoparathyroidism. Genistein may benefit bone health in postmenopausal women but more data are needed to fully understand its effects on bone health and fracture risk. These medications vary chemically from alendronate, ibandronate, risedronate and zoledronic acid but are in the same drug class. This medication is approved in some countries in Europe for treatment of osteoporosis in women. Through a process that is still unclear, sodium fluoride stimulates the formation of new bone. The quality of bone mass thus developed is uncertain, and the evidence that fluoride reduces fracture risk is conflicting and controversial. This medication is approved for the treatment of osteoporosis in some countries in Europe. Strontium ranelate reduces the risk of both spine and non-vertebral fractures, but the mechanism is unclear. Incorporation of strontium into the crystal structure replacing calcium may be part of its mechanism of effect. These effects have only been documented with the pharmaceutical grade agent produced by Servier. This effect has not been studied in nutritional supplements containing strontium salts. Tibolone is a tissue-specific, estrogen-like agent that may prevent bone loss and reduce menopausal symptoms. It is indicated in Europe for the treatment of vasomotor symptoms of menopause and for prevention of osteoporosis, but it is not approved for use in the U. Monitoring Effectiveness of Treatment It is important to ask patients whether they are taking their medications and to encourage continued and appropriate compliance with their osteoporosis therapies to reduce fracture risk. It is also important to review their risk factors and encourage appropriate calcium and vitamin D intakes, exercise, fall prevention and other lifestyle measures. Furthermore, the need for continued medication to treat osteoporosis should be reviewed annually. Some patients may be able to discontinue treatment temporarily after several years of therapy, particularly after bisphosphonate administration. Accurate yearly height measurement is a critical determination of osteoporosis treatment efficacy. Measurements for monitoring patients should be performed in accordance with medical necessity, expected response and in consideration of local regulatory requirements. Precision of acquisition should be established by phantom data and analysis precision by re-analysis of patient data. Peripheral skeletal sites do not respond with the same magnitude as the spine and hip to medications and thus are not appropriate for monitoring response to therapy at this time. Biological variability can be reduced by obtaining samples in the early morning after an overnight fast. Serial measurements should be made at the same time of day at the same laboratory. Vertebral Imaging: Once the first vertebral imaging test has been performed to determine prevalent vertebral fractures (indications above), repeat testing should be performed to identify incident vertebral fractures if there is a change in the patient’s status suggestive of new vertebral fracture, including documented height loss, undiagnosed back pain, postural change, or a possible finding of new vertebral deformity on chest x-ray. If patients are being considered for a temporary cessation of drug therapy, vertebral imaging should be repeated to determine that no vertebral fractures have occurred in the interval off treatment. A new vertebral fracture on therapy indicates a need for more intensive or continued treatment rather than treatment cessation. These programs have accomplished a reduction in secondary fracture rates as well as health care cost 100,101 savings.
Table 6: Administration of oral quinine (salt buy 10mg levitra visa, 300 mg tablet) for different age groups Age (years) Number of tablets per dose <1 0 buy levitra 20mg amex. Appropriate management of treatment failure or non- response is important because the patient may progress to severe malaria generic levitra 20 mg on-line, and resistant parasites may be present and transmitted to others. The tasks to be carried out at this level include: • Recognize the symptom of fever and danger signs (see Chapter 2) and promptly seek appropriate care. Tasks at this level include: • Carrying out diagnoses according to their training and recognizing danger signs. In addition, measures to reduce body temperature should be recommended, such as tepid sponging, fanning, and giving paracetamol. Follow-up should be conducted with patients, particularly children below five years and pregnant women. Referred patients should be accompanied to the health facility or a referral letter sent with the patient indicating treatment given and when. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 44 Criteria for referral to a health facility (Appendix A1): • All pregnant women with fever. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 45 Chapter 6: Management of Severe Malaria P. Delay in diagnosis and appropriate treatment may lead to serious complications and even death. The key features of effective case management of severe malaria are early recognition, assessment by a qualified health worker, referral to a higher facility where necessary, and appropriate antimalarial and supportive therapy. The following laboratory investigations should be done whenever severe malaria is suspected and laboratory capacity is available at the health facility level. Measuring creatinine and electrolytes is most valuable when acute renal failure threatens or develops. None of these investigations should delay treatment in a Guidelines for the Diagnosis and Treatment of Malaria in Zambia 47 patient who is suspected of having severe malaria! All life-threatening conditions and the presence of any danger sign in a patient with fever and parasitological evidence of malaria should be considered as possible severe malaria and referred to a facility or admitted to hospital without delay for appropriate management. Weigh patient (particularly children), if possible, and calculate dosage per body weight. Make rapid clinical assessment and look for signs of meningitis and other conditions. Start treatment for hypoglycaemia, meningitis and other conditions where indicated. Plan first 8 hours of intravenous fluids, including diluents for antimalarial medicine, glucose therapy, and blood transfusion, if necessary. Children with metabolic acidosis may benefit from a Guidelines for the Diagnosis and Treatment of Malaria in Zambia 49 resuscitation bolus of fluid, preferably a plasma expander such as normal saline. The most common indication for blood transfusion is severe anaemia (Hb less than 5 g/dl). The decision whether to transfuse should not rely only on the haematocrit and/or Hb level but should also be based on assessment of the patient’s overall medical condition. A central venous pressure line may be necessary if pulmonary oedema is suspected and may be useful in a patient with shock or impending renal failure. For patients in coma or respiratory distress, the need for intubation and mechanical ventilation may be considered. Dilute with 5 ml of 5% dextrose solution or water for injection or normal saline (0. Withdraw into syringe and inject intravenously over 5 Guidelines for the Diagnosis and Treatment of Malaria in Zambia 51 minutes. Each vial of injectable artesunate must be reconstituted with 1 ml of sodium bicarbonate, which is supplied together with the vial of artesunate. Shake for 2 to 3 minutes until the powder is completely dissolved and the solution is clear. Dilute with 2 ml of 5% dextrose solution or water for injection or normal saline (0. After initial parenteral treatment for a minimum of 24 hours, once the patient regains consciousness and can take medications orally, discontinue parenteral therapy and commence full course of artemether-lumefantrine. There should be an interval of at least 8 hours between the last dose of artesunate and the first dose of artemether/lumefantrine. After 8 hours, give a maintenance dose of 10 mg/kg body weight over 4 hours, repeated every 8 hours until patient can swallow, then oral quinine 10 mg/kg body weight every 8 hours to complete a 7-day course of treatment. This should be given preferably on the Guidelines for the Diagnosis and Treatment of Malaria in Zambia 53 anterior thigh. After 8 hours, give a maintenance dose of 10 mg/kg body weight (maximum 600 mg) over 4 hours, repeated every 8 hours until patient can swallow or after coma resolution, then oral quinine 10 mg/kg body weight every 8 hours to complete a 7-day course of treatment. The drip rate is calculated as follows: Drip rate per minute = Amount of fluid to be given x 20 (drop factor) Time in minutes over which to be given Guidelines for the Diagnosis and Treatment of Malaria in Zambia 54 6. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 55 Table 8: Key observations and their implications for patients with severe malaria Regular Possible Abnormal Observation Appropriate Action Observation (Clinical signs) Axillary If temperature remains Give paracetamol if not temperature high> 38. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 59 Chapter 7: Managing Complications of Severe Malaria 7. Crushed paracetamol tablets or syrup (15 mg/kg) may be washed down a naso- gastric tube. Tepid sponging, exposure, and fanning are also effective ways of reducing temperature. They are common in children with severe malaria but are relatively rare in adults. Guidelines for the Diagnosis and Treatment of Malaria in Zambia 60 • Monitor vital signs (temperature, pulse rate, respiratory rate, and blood pressure). Insert about 5 cm length of a naso- gastric tube into the rectum, inject the diazepam into the naso-gastric tube and thereafter flush with 5 ml of water. Note: Make sure the patient has received glucose and that Guidelines for the Diagnosis and Treatment of Malaria in Zambia 61 the temperature is controlled. Indication for urgent blood transfusion Blood transfusion should be considered if the haematocrit falls below 15% or haemoglobin concentration is < 5 g/dl. Packed cells should be given; in cases of hypovolemic shock, whole blood is preferred. Patients with very low Hb may also have the following conditions: • Signs of heart failure • Signs of respiratory distress • Hyperparasitaemia • Impaired consciousness Management of life-threatening anaemia (Hb < 5 g/dl) Guidelines for the Diagnosis and Treatment of Malaria in Zambia 62 associated with malaria • Administer oxygen 2. How to administer blood Packed cells are given at l0 ml/kg and whole blood at 20 ml/kg. An intravenous stat (bolus) dose of a loop diuretic like furosemide at 1 to 2 mg/kg may be given (provided the blood pressure is not low) during blood transfusion to avoid circulatory overload. Drip: drops/mm = Volume to be transfused in ml x 20 (or 15) drop factor Time of transfusion in hours (4 to 6 hours) x 60 minutes 1 ml whole blood = 20 drops l ml packed cell = 15 drops Fresh blood is preferred because it contains clotting factors and platelets.
Accreditation has come to be thought of as a ―stamp of approval‖ verifying the authenticity and quality of the services provided buy cheap levitra 10mg line. Potential problems with accreditation include: The commercial needs and aspirations of the accreditation schemes themselves may be allowed to dominate the picture buy cheap levitra line. Many (but not all) of the accreditation schemes operating internationally are private companies or corporations purchase levitra with a mastercard. Standards are at the heart of accreditation, and they must be directed towards those factors that may make a difference to the quality of care. Accreditation schemes should be fit for purpose, based on the results of the best available research, and sensitive to change. There are therefore three categories of area where accreditation is of interest to the medical tourism market: a) Offering assurance to commercial interests of the quality and safety of the product they are selling to the public, which in turn may reduce their liability and minimise bad publicity in the future. Currently, there is no universal ―official agency/group‖, such as the United Nations, the World Health Organization, the World Tourism Organization or the World Trade Organization, engaged in either the delivery of accreditation, the co-ordination of delivery of accreditation, or licensing or studying the existing schemes that deliver accreditation. Mandatory accreditation may appeal to governments and commercial healthcare purchasers such as third-party payers (e. Accreditation has most often been used as a marketing tool by wealthier provider hospitals, medical tourism facilitators and the governments of provider countries seeking to grow their share of the medical tourism business. Some places may be simultaneously acting as countries of origin and destination in the medical tourism marketplace. High-income countries may service overseas elites whilst at the same time their citizens choose to travel as medical tourists to Lower and Middle Income Countries for treatments. Conversely, the emergence of lower- cost treatments in Thailand, India or parts of Eastern Europe will attract individuals from higher incomes countries who pursue treatments on the basis of cost. This section focuses on the implications for countries from the perspective of them being an origin or source of medical tourists. In trade parlance, this concerns the services that a country imports (if their patients go overseas to receive care, then effectively they are importing a service). It explores a range of financial, social, political, ethical and legal issues, and implications for local industry. It is also the case that not all medical tourism is treatment ‗on the cheap‘ – travel to countries for experimental treatment may consume considerable family resources (Song, 2010). This assertion of choice and autonomy may, however, lead to externalities at the system level. There are a range of financial impacts for source countries that may arise for the publicly funded health care system. Costs may result from overseas cosmetic surgery or dental work that requires emergency or remedial treatment within home countries (Cheung and Wilson, 2007, Jeevan and Armstrong, 2008, Healy, 2009). Infection outbreaks resulting from travel will also bring their own costs (cf Newman et al. Similarly, there may be health and social care costs that arise from multiple births (cf Ledger et al. But there has been little systemic collection of evidence or attempts to estimate overall system costs. There are also potential impacts on private health activity – given that they potentially lose business to overseas providers, for example cosmetic surgery. There are associated costs of patients travelling overseas – the necessity to monitor/regulate advertising and provide detailed information and advice to support potential or actual medical tourists carries its own costs. There is the likelihood that large numbers of medical tourists will impact on the source country‘s own health system, perhaps increasing trends that are encouraged by the current domestic private provision. Such flows also reduce the pressure for investment in particular facilities and technology. Indeed, there is an argument that some types of outflows of medical tourists for treatments that could be provided locally signal a failure of policy and delivery in the sender country. But it is also within higher income countries where the possibilities of a exacerbating two-tier system can emerge. If, for example, eligibility for services such as fertility or dental work is tightened, then 30 those with private resources may choose to travel overseas to maintain access (thus exercising choice and exit). Patients who are able to circumvent waiting times highlight the familiar issues of access and equity. In those countries where third-party insurers are exploring medical tourism as a provider option, those that are insured under these plans – perhaps unable to get alternative cover – may find themselves disadvantaged. Clearly, however, source-country payers may benefit from outflows of patients – including employers and employees contributing to health plans, and the public insurance system itself. There may be some opportunities for financial benefit if medical tourism is an option. Mattoo and Rathindran (2006), for example, highlight that for the United States 15 treatment that would show savings of $1. Some subsets of the population, such the Indian Diaspora, may prefer to go back ―home‖ for treatment, and may be happy to cross-subsidise some of the costs, or may not need an accompanying adult, further increasing the amount saved. Plausibly, the health systems within source countries could develop relations with off-shore medical tourism facilities to leverage cost savings – providing individuals with a choice of overseas destinations. This could also reduce waiting lists – and reflects a form of outsourcing or more ‗collective‘ medical travel (Smith et al. One of the drivers for medical tourism is price because treatments may often be available locally within the private sector, but at greater cost. There are arguments that some medical systems are inefficient and face restrictive barriers to entry. A development such as medical tourism can potentially exert competitive pressure on systems importing health care and help drive down the costs and prices offered in domestic systems (Herrick, 2007). Medical tourism may encourage economies to maximize their comparative advantage in labour costs, technology and/or capacity. We have seen in Section 4 that source counties – or those importing health services – may benefit from medical tourism through alleviating waiting lists and lowering healthcare costs, but may risk quality of care and legal liability. In this section we turn our attention to destination countries – or those exporting health services. Medical tourism has historically been from lower to higher income countries, with better medical facilities and more highly trained and qualified professionals. However, this trend is now reversing, and most recently ―hubs‖ of medical excellence have developed which attract people regionally (Horowitz et al. The main importing countries (those where the medical tourists come from) are in North America and Western Europe. Although current levels of movement are relatively limited, as outlined in Section Four , the potential, if payment was covered by third-party payers, is significant. The main exporting countries (those who provide the services to medical tourists) are located across all continents, including Latin America, Eastern Europe, Africa and Asia. For instance, Thailand and India specialise in orthopaedic and cardiac surgery, whereas Eastern European countries are hotspots for dental surgery (Smith et al. Nonetheless, many of the issues are quite generic and will affect any destination country, regardless of the level of economic development, just to a greater or lesser extent.
9 of 10 - Review by L. Gancka
Votes: 285 votes
Total customer reviews: 285